Novel Laser treatments using Mid-infrared tunable Laser Kunio AWAZU Mid-infrared (MIR) laser with a specific wavelength can excite the corresponding biomolecular site to regulate chemical, thermal and mechanical interactions to biological molecules and tissues. In laser surgery and medicine, tunable MIR laser irradiation can realize the safety regulation of therapeutic effect, less-invasive treatments and the special diagnosis by vibrational spectroscopic information. Recently, the developments of table-top light sources with wavelength tunability have made progress and optical parametric oscillation (OPO), difference-frequency generation (DFG) and quantum cascade laser (QCL) etc. have started to become widely used at a laboratory level. Consequently, application studies in a MIR region have gained recognitions. MIR wavelengths correspond to the molecular stretching and vending vibrations. Thus MIR tunability means to be able to provide MIR photon energies with a specific target, molecular bonds and functional groups, by the irradiation with a wavelength corresponding to a molecular vibration. MIR laser irradiation can realize a limitation of therapeutic effects and an inhibition of side effects and leads to less-invasive treatments. In order to get the less-invasive treatment effects, it is essential to determine the molecular vibrations (i.e. IR absorption) of a target before treatments using MIR lasers. In this talk, Based on the laser tissue interaction, I introduce a novel therapeutic and diagnostic applications using tunable MIR pulsed laser by DFG method. Specifically, I show the studies about less-invasive laser angioplasty with a wavelength of 5.75 um and IR spectroscopy of biological samples using tunable IR laser with a wavelength range from 5.5 um to 10 um.
FOR CARDIOVASCULAR SURGERY Masayoshi Okada1, Masato Yoshida 2 and Yoshihiko Tsuji3
International Institute for Advanced General Medicine
Himeji Cardiovascular Center
(Purpose): Recently, much attention has been paid to check many kinds of treatments for cardiovascular surgery. In 1980,we have tried a laser application for the treatments in cardiovascular surgery. That is, 1)Laser application for end-stage of ischemic heart disease(Transmyocardial laser revascularization), 2) Laser vascular anastomosis, 3) Endovascular laser treatments were carried out by ourselves. On the basis of experimental excellent results, clinical applications were performed .
(Materials and methods): 1) high power energy of CO2 laser was used for transmyocardial revascularization with safety and its efficacy. It was enough laser energy more than 90 watts to make a laser of transmyocardial tunnel, which was opened for 3 years after creation of new tunnel. 2) low power energy of CO2 was also utilized for laser vascular anastomosis. It was enough of 20-40 mW in output, and 6-12 sec/mm in irradiation time, 3) Argon-laser was applied with 200℃in output and 5 sec in irradiation time for each shot in endovascular diseases.
(Results): 1)Transmyocardial laser revascularization was clinically done on 21. Nov. 1985. Postoperative course was uneventfle. This was a first successful clinical patient in the world, 2) Laser vascular anastomosis was performed in 111 patients with intermittent claudication and angina attack. All cases are doing well without any complications through the laser vascular anastomosis. 3) Endovascular interventions were carried out for the 115 patients with several kinds of stenotic and occlusive lesions. Their results were satisfactory by laser treatment.
(Conclusion): Laser treatment should be recommended for coronary and peripheral arteries diseases in cardiovascular surgery.
Special Lecture- 3 (SPL-3)
Peregrinations through the Orient Isaac Kaplan My involvement in spreading the gospel related to CO2 laser surgery in the Aseo Pacific region both through the APSLMS
and otherwise will be reported with special reference to the cities attended.
Special Lecture- ４ (SPL-４)
History of LLLT Toshio Ohshiro Background: ‘Low reactive- Level Laser Therapy’ and its acronym, LLLT, were first coined in 1987as the acronym, LLLT when authored of the book, “Low Level Laser Therapy: a Practical Introduction” published by John Wiley & Sons, Chichester, UK. At the same time Wiley also published the Pilot Issue of the journal, Laser Therapy, with myself as Editor-in-Chief. Both publications were successfully exhibited at the joint congress of major European and International Laser Societies, July 19th 1987. Within one day, one thousand copies of pilot issue had been distributed, a very rare event at top medical congresses, even in John Wiley and Sons’ exhibition history.
Formation of ILTA: A number of interested leaders in the phototherapy field, including Adam Mester, son of the Father of Phototherapy, Professor Endré Mester, felt that we should have a dedicated LLLT society, and so the Steering Committee of the International Laser Therapy Association (ILTA) was formed on July 20th, with myself elected as president. In 1990, the 1st ILTA Congress was very successfully held in Okinawa, Japan.
Terminology: After Okinawa, the term LLLT became well-used rather than laser biostimulation. I added the term ‘photobioactivation’ to cover the research field. Incorrect terminology was too common, however, with nonscientific marketing-driven terms such as soft laser, cold laser and low power laser. To help clarify the situation, I evolved a new therapeutic effect-based classification system for LLLT, based on Ohshiro’s Laser Apple, to separate LLLT for laser surgery, or high reactive-level laser treatment (HLLT), and further subdivided LLLT into pure-LLLT and autosimultaneous LLLT, the latter being used to describe the photoactivative effects accompanying laser surgery.
Conclusions: With the advent of non-laser sources such as light-emitting diodes, the original LLLT is now expressed as ‘Low Level LIGHT Therapy’, expounded by Professor Kendric C Smith. Nearly at its quarter-century, LLLT is alive and well!
Special Lecture- 5 (SPL-5)
“ From Tel Aviv to Bangkok, via Tokyo”
Prof. Narong Nimsakul, M.D., F.I.C.S.
Honorary President, Asian-Pacific Association for
Laser Medicine & Surgery. In February 1977, I went to study Laser Surgery from Prof. Isaac Kaplan at Beilinson Hospital, Tel Aviv University, Israel. It was the first time in my life to see, touch and know Co2 Laser machine functioning.
Then we got the first sharplan-791 Co2 Laser of 50 Watt output to Japan, at Department of Plastic Surgery, Tokai University in May 1977.
I joined the 2nd Congress of the International Society for Laser Surgery, at Baylor University, Dallas, USA in October 1977, and reported our first paper then.
We then organized Symposia and Scientific meetings, and formed the Japan Society for Laser Medicine in late 1977, with Prof. Kazuhiko Atsumi as our first President.
Then Japan has progressed rapidly with R & D in Laser Surgery and Medicine, many industrial companies participated in manufacturing of the Laser systems, and Japan hosted the 4th Congress of the International Society for Laser Surgery & Medicine in 1981 successfully, stimulated the interest amoung the Asian countries.
In 1985, we organized the first Congress of the Asian-Pacific Association for Laser Medicine & Surgery in Tokyo, under the Presidency of Prof. Kazuhiko Atsumi.
wares with Japanese colleagues until 1992, then moved back to Bangkok, Thailand. Some of the works are
(1).With NIIC, developed portable Co2 Laser system, Coaxial CO2-YAG system, centralized system of Co2, Argon, and Nd: YAG at the world first centralized Laser Hospital at Nanasato.
(2).With Japanese Government Project, developed and clinical tested CO2 Laser transmitted with optical fiber (KRS-5).
(3).With SLT-Japan, developed Sapphire-contact tips for Nd: YAG Laser.
I hosted the 10th Congress of the International Society for Laser Surgery and Medicine at Bangkok, in November 1993, and hosted the 9th Congress, Asian-pacific Association for Laser Medicine & Surgery, October 2002 at Pattaya.
I became the organizational President of Thailand Society for Laser Medicine & Surgery in 1985, and continued to be the President until 1996.
Thailand as member of the ASEAN, which will become ASEAN ECONOMIC COMMUNITY of 10 nations in 2015, with 600 millions population, will try to be the medical hub of Asia, by integrating the Tele-medicine, Integrative Medicine with Laser Technologies as tools for promoting Medical Tourism, and we want to co-operate with the Asian-Pacific members, the US, and the EU members, to make Laser technology beneficial to health and wellness of the World population.
Special Lecture- 6 (SPL-6)
Review of Laser Surgery and Medicine in Taiwan Ming-Chien Kao Emeritus Professor, Neurosurgery, National Taiwan University
President, Laser Medicine Foundation, R.O.C.
Founder President of Laser Medicine Society, R.O.C.
The Laser Medicine Society of Taiwan was established at Dec. 1984.
The CO2 Surgical laser was first introduced at 1975 by Dr. Kaplan.
The Argon laser was introduced at 1977 for ophthalmology application.
The Bulletin of the Society established since 1985.
The Laser Medicine Research Center was established in 1987 at National Taiwan University.
The laser medicine curricula started from 1987 at the College of Medicine, National
Basic laser medicine for junior class. Clinical laser medicine for senior class.
The Asian Pacific Laser Medicine Society (July, 1985, Tokyo)
The 6th Congress of ISLSM (Oct. 1985, Jerusalem)
The 7th Congress of ISLSM (June, 1987, Munich)
The 8th Congress of ISLSM (Nov. 1989, Taipei)
The 4th Congress of European Laser Association (July, 1988, London)
Clinical application of low power lasers (Aug. 1988, Tokyo)
Contact Nd-YAG laser (Jan. 1989, Taipei)
Proceedings of the 8th Congress of ISLSM (Nov. 1989, Taipei)
The 2nd World Congress of low power laser application in medicine (Sept. 1989, Tokyo)
Laser Laparoscopic Cholecystectomy (Training box for endoscopic surgery)
International Congress of Photodynamic Therapy and Laser Medicine Society (Oct. 1991, Peking)
Cell Scan System (Feb. 1993, National Taiwan University)
Excellent Paper Awards (Feb, 1993)
Excimer laser for refractory surgery (1994)
Laser application in dentistry (1995)
Laser assisted uvla palatoplasty (1995)
Ultrapulse CO2 laser for skin rejuvenation (1996)
Laser hair transplantation (1996)
Q-switched ruby laser for Ota nevus (1997)
The 6th Congress of Asian Pacific Society of Laser Medicine and Surgery (1996, Seoul)
The 9th Congress of International YAG Laser Symposium (1997, Taipei)
Percutaneous laser disc decompression (1997)
Interstial photodynamic therapy for prostate hypertrophy
International Symposium on Optoelectronic Biotechnology and Laser Medicine (April, 1999, Taipei)
Intralase + Wavefront + LASIK (2005)
Dermatology excimer laser
Anti-Aging Symposium (2005, Taipei)
Q-switched YAG laser for tattoos (2005, Taipei)
First Congress of World Federation of Societies for Laser Medicine and Surgery (Sept. 2005, Tokyo)
Regular teaching and training courses for cosmetic laser nurses(2006-2010, Taichung, Kaohsiung)
Recent clinical studies and basic researches of laser application in medicine(2009-2010, Taiwan)
Laser Tokyo 2009, WFSLMS, APALMS, International Laser License System(ILLIS)
The 13th Congress of APALMS(Oct.8~9, 2010, Suwa Nagano, Japan)
The 14th Congress of APALMS(Nov.23~25, 2012, Taipei, Taiwan)
Special Lecture- 7 (SPL-7)
Recent progress of PDT in lung cancer Harubumi Kato Department of Surgery, Niizashiki Central General Hospital, Saitama, Japan Author will present recent progress of PDT in lung cancer.
It is very important how to detect patients indicated PDT, how to localize the lesions, how to decide the indication, how to choose the tumor specific photosensitizers and the lights for excitation, and how to treat.
The indication of curative PDT is early stage central type lung cancer which has been already approved as an internationally standard therapy. Sputum cytology is the most effective method for the detection, particularly in the smokers. Then at the next step, endoscopy is effective for the localization. However sometimes lesions can not be recognized because of too early lesion. In such occasions the fluorescence bronchoscopy is useful for the localization. Fluorescence bronchoscopy is not only available for early localization but effective for the evaluation of reaction of PDT. A new tumor-specific photosensitizer, Lasephyrin was developed and was approved for clinical use by the Japanese government in 2004. This new drug shows better tumor response than previous Photofrin and extremely low photosensitivity of the skin due to the rapid metabolism.
PDT is an ideal local treatment which can preserve the organ function, the indication of PDT is the most important for the curative result. The indication must be limited in the superficial early stage lung cancer without any metastases. Optical coherence tomography is a useful tool for the evaluation of depth of tumor invasion of the bronchus.
Special Lecture- 8 (SPL-8)
“The Great History of APLMS”
Kazuhiko Atsumi M.D., PhD. Prof. Emeritus Tokyo University
The Founder of APLMS The First Congress on ASLMS was held in Tokyo presided by myself in 1985.
The purpose is to promote Laser Surgery and Medicine in Asian Pacific region.
The objectives have been focusing to stimulate medical doctors and scientist and also to educate citizens, commercial peoples and governmental officers by scientific meetings.
Until now, the 12th conferences have been continuing and contributing to health and welfare in Asian Pacific regions’ countries.
The main events and great efforts of each country’s leaders will be shown in the presentation.